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Ischemia–reperfusion injury is a leading cause of acute renal
failure and a major determinant in the outcome of kidney
transplantation. Here we explored systemic gene therapy
with a modified adenovirus expressing Interleukin (IL)-13, a
cytokine with strong anti-inflammatory and cytoprotective
properties. When ischemia was induced we found that the
IL-13 receptor is expressed in both the normal and
experimental kidneys. Prior to the induction of ischemia,
rats received adenovirus-IL-13, control adenovirus or saline.
IL-13 plasma levels increased more than 50-fold in
adenovirus-IL-13 treated animals, confirming successful
IL-13 gene delivery. Histological analysis showed decreased
tubular epithelial cell damage with adenovirus-IL-13 therapy,
accompanied by reduced kidney injury molecule-1
expression. Interstitial infiltration by neutrophils and
macrophages was reduced by half as was interstitial fibrosis
and expression of a-smooth muscle actin. IL-13 treatment
significantly diminished the expression of E-selectin, IL-8,
MIP-2, TNF-a and MCP-1 mRNA. These results suggest that
the use of systemic IL-13 gene therapy may be useful in
reducing renal tubulointerstitial damage and inflammation
caused by ischemia–reperfusion.
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Renal ischemia–reperfusion (I/R) injury remains the leading
cause of acute renal failure and is a major determinant in the
outcome of kidney transplantation. In renal transplantation,
I/R may delay graft functioning1 and increase its immuno-
genicity,2,3 thereby further augmenting the risk of graft
failure. Renal I/R injury, in principle a reversible condition, is
initially marked by massive tubulointerstitial damage,
followed by tubular regeneration and restoration of structure
and function. However, depending on the severity of the
initial insult and the presence of other aggravating factors, I/
R damage may trigger or accelerate the development of
chronic renal failure.4,5
The absence of renal blood supply during severe ischemia
and the subsequent reperfusion activates a complex cascade
of events characterized initially by tubular epithelial cell
damage, activation of endothelial cells, and increased
microvascular permeability with edema.6 The acute inflam-
matory reaction triggered by I/R involves the release of
proinflammatory cytokines and chemokines7 and infiltration
of neutrophils, which aggravate tissue injury8 through release
of reactive oxygen species, proteases, and chemoattractant
molecules.9 Later on, as a consequence of production of
proinflammatory cytokines and chemokines by both resident
and inflammatory cells, macrophages accumulate in the
kidney.10,11 Although fundamentally regulated toward restor-
ing normal structure and function, a strong inflammatory
response may further aggravate the initial insult, contributing
to chronic tubulointerstitial fibrosis.12,13
The beneficial effects of interleukin (IL)-13, a Th type 2
cytokine, have been widely acknowledged, as IL-13 suppresses
the acute inflammatory response and displays potent
cytoprotective properties. In vitro, IL-13 suppresses mono-
cyte-derived proinflammatory cytokines, tumor necrosis
factor-a (TNF-a), IL-1, IL-6, IL-8, and macrophage inflam-
matory protein-1a (MIP-1a),14,15 while stimulating produc-
tion of IL-1 receptor antagonist.16 Moreover, IL-13 displays
antiapoptotic17,18 and antioxidant19 properties. In vivo, both
endogenous and exogenous IL-13 protect from sepsis-
induced lethality20,21 and from liver injury induced by both
warm and cold ischemia followed by reperfusion.19,22,23 The
effects of IL-13 are mediated through a receptor system
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composed of IL-4 receptor (R)a, IL-13Ra1, and IL-13Ra2.
The complex IL-4Ra/IL-13Ra1 mediates most of the IL-13
effects, whereas IL-13Ra2 functions mainly as a decoy
receptor.24
As IL-13 protein has a short half-life,25 gene transfer
approaches may considerably improve IL-13 therapeutic
strategies. Taking advantage of the natural homing of
adenovirus to the liver, it was shown previously that
adenovirus-delivered IL-13 protects from liver I/R injury
after intravenous injection.23 Furthermore, local adenovirus-
IL-13 gene transfer was used as an effective treatment for
rheumatoid arthritis.26,27 To deliver IL-13 systemically, we
have chosen an adenovirus-based gene therapy approach. As
human (h)IL-13 has been previously shown to be more
potent than the rat IL-13 in rats,26 we have used hIL-13 gene
in our study. In addition, an RGD (Arg–Gly–Asp) modifica-
tion of the adenovirus increases its transduction efficiency.28
Therefore, we studied the effects of hIL-13 on renal I/R injury
using a systemic, intramuscular RGD adenovirus-delivered
gene therapy approach in a rat model of warm renal I/R.
RESULTS
IL-13 plasma levels
First, the natural course of rat (r)IL-13 plasma levels during
renal I/R was studied in rats treated with saline, 2 days before
the induction of I/R (day 2), at the time of I/R (day 0), and
at the end of the reperfusion (90 min, 6 h, days 1, 4, and 14).
I/R induced a slight decrease in rIL-13 plasma levels, reaching
statistical significance on day 1 (Figure 1a).
Further, the effect of IL-13 on renal I/R was studied.
hIL-13 was delivered by intramuscular injection of an RGD-
adenovirus-IL-13 (RGD-AdTIL-13) at day 2. The hIL-13
plasma levels were determined in blood samples collected at
day 2, at day 0, and at the end of the reperfusion (Figure 1b).
The IL-13 levels of RGD-AdTIL-13-injected rats increased
approximately 50 at day 0 (209.64±22.71 pg ml1)
compared with day 2 (3.84±0.81 pg ml1) and returned
to baseline by day 14 (12.21±5.14 pg ml1). In contrast, the
hIL-13 levels did not change in the control groups (saline and
control-virus). After intramuscular injection of control-virus
(RGD-AdTL) or RGD-AdTIL-13, green fluorescent protein
(GFP)-positive cells were found only in the injected muscles,
all the other organs studied, including the liver, being
negative for GFP (data not shown).
IL-13 preserves renal structure and function
Renal histology and plasma creatinine levels were studied at
day 1 after I/R, a time point at which renal structure and
function are the most affected by I/R.29,30 Microscopical
assessment of renal tissue revealed severe tubular necrosis,
loss of brush border, tubular intraluminal cell debris, and
protein casts, the most dramatic changes being observed in
the outer medulla (Figure 2a). RGD-AdTIL-13 significantly
diminished the renal damage in the outer medulla compared
to the control groups (Figure 3a) and limited the extension of
tubular damage into the cortex (Figure 3b). The number of
proliferating (Ki67-positive) tubular epithelial cells increased
significantly on day 1 compared to sham (Table 1, Po0.01).
However, there was no significant difference in the number of
proliferating cells between the groups (P40.05).
Despite the rat model featuring one unaffected kidney, I/R
induced a slight but significant increase in creatinine plasma
level at day 1 (Figure 3c, saline: 53.7±1.9; RGD-AdTL: 52.2±
1.5 mmol l1) compared with sham (42.2±0.5 mmol l1).
RGD-AdTIL-13 therapy restored plasma creatinine to normal
levels (45.2±1.5 mmol l1, P40.05 vs sham). Moreover, the
creatinine plasma levels correlated positively with histological
damage in I/R kidneys at day 1 (Figure 3d).
IL-13 reduces tubulointerstitial damage inflicted by I/R
Expression of KIM (kidney injury molecule)-1, a marker of
ischemic tubular damage,31 was assessed by immunohisto-
chemistry. Although KIM-1 was absent in the sham-operated
animals, its expression gradually increased after I/R, reaching
a maximum at day 1 (Figure 4). At 6 h, KIM-1-positive cells
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Figure 1 |The time course of IL-13 plasma levels. (a) Rat IL-13
plasma levels during renal I/R. Rat IL-13 plasma levels were measured
with ELISA 2 days before the I/R operation (day 2, n¼ 6), at the time
of I/R (day 0, n¼ 6), and at 90min, 6 h, 1, 4, and 14 days after I/R
operation (end of reperfusion, n¼ 5–6 per time point), respectively.
Rat IL-13 levels decreased significantly on day 1 after I/R compared
with the levels before the induction of I/R (*Po0.05). (b) Human IL-13
plasma levels after intramuscular treatment and I/R. Human IL-13
plasma levels were measured using ELISA at day 2, at day 0 (n¼ 25
for saline and for RGD-AdTIL-13, n¼ 22 for RGD-AdTL), and at the end
of the reperfusion (n¼ 5–6 per time point for RGD-AdTIL-13 and n¼ 3
per time point for saline and for RGD-AdTL). After injection of RGD-
AdTIL-13, human IL-13 plasma levels increased approximately 50 at
day 0 compared to day 2, reached a maximum at day 4, and
returned to baseline at day 14. In the saline and RGD-AdTL-treated
rats, IL-13 plasma levels did not significantly vary in time. #Po0.01
compared to saline and RGD-AdTL treatment.
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were occasionally seen in the outer medulla. At day 1, KIM-1
was abundantly present in tubular structures of the outer
medulla with focal cortical extensions (Figure 2b). At day 14,
KIM-1 was observed only in dilated tubules with flattened
epithelium (data not shown). RGD-AdTIL-13 therapy
significantly diminished the amount of tubular KIM-1 in
both the outer medulla and the cortex.
Expression of interstitial a-smooth muscle actin (a-SMA),
a marker of renal prefibrosis, was also studied. In the sham-
operated rats and I/R rats at 90 min and 6 h, a-SMA
expression was limited to arteries. At day 1, 4, and 14,
de novo a-SMA expression in the peritubular interstitial
compartment was found, reaching a maximum at day 4
(Figure 5a). At day 4, a-SMA was uniformly expressed
throughout the interstitium (Figure 2c), whereas at day 14,
a-SMA was localized preponderantly around the dilated
tubules (data not shown). RGD-AdTIL-13 treatment reduced
a-SMA expression by approximately 50%.
To investigate the fibrotic changes after I/R, we deter-
mined the expression of collagen III at day 14. Collagen III
PAS
KIM-1
SMA
Collagen III
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Figure 2 |Protective effects of IL–13 against histological damage and inflammatory cell infiltration. Representative pictures from
(immuno)histology, showing (a) diminished histological damage (PAS staining, day 1, original magnification  200), (b) reduced KIM-1
expression in tubular epithelial cells (day 1, original magnification  100), (c) less interstitial a-SMA expression (day 4, original magnification
 100), (d) less interstitial collagen III deposition (day 14, original magnification  100), (e) reduced infiltration with neutrophils (day 1, original
magnification  200), and (f) reduced infiltration with macrophages (day 4, original magnification  200) under RGD-AdTIL-13 therapy (fourth
panel) in comparison with saline (second panel) and RGD-AdTL therapy (third panel). (b–f) Positive structures are stained in brown. Pictures
from sham-operated rats are shown in the first panel.
1366 Kidney International (2008) 73, 1364–1373
or ig ina l a r t i c l e M Sandovici et al.: IL-13 and renal ischemia–reperfusion injury
expression increased approximately sixfold in both the I/R
control groups compared to sham (Figure 5b), being
predominantly seen in the areas surrounding dilated tubules
(Figure 2d). RGD-AdTIL-13 therapy diminished collagen III
expression by approximately 35%.
IL-13 limits neutrophil and macrophage infiltration
The sham-operated rats exhibited only few neutrophils (HIS-
48þ ) in the interstitium. After I/R, neutrophils infiltrated
especially the outer medulla (Figure 2e) and to a limited
extent the cortex. In the outer medulla, the number of
neutrophils increased significantly at 6 h, reached a maxi-
mum at day 1, and returned to normal levels by day 14.
RGD-AdTIL-13 therapy significantly decreased the number
of neutrophils (Figure 6a).
In the sham-operated rats, there was a limited number of
macrophages (ED-1þ ) in the interstitium. After I/R,
macrophages infiltrated both the medulla and the cortex.
At day 1 and 4, most of the macrophages infiltrated the outer
medulla (Figure 2f), whereas at day 14, macrophages were
abundantly present around the dilated tubules (data not
shown). RGD-AdTIL-13 therapy diminished the macrophage
influx by approximately 50% (Figure 6b).
IL-13 downregulates E-selectin, IL-8, macrophage
inflammatory protein-2, TNF-a, and monocyte
chemoattactant protein-1 mRNA
To get insights into the mechanism of IL-13-mediated
protection against I/R injury, we studied the expression of
heme oxygenase 1 (HO-1).32,33 I/R induced a rapid 10-fold
upregulation of HO-1 mRNA compared to sham (Figure 7a).
RGD-AdTIL-13 attenuated the HO-1 mRNA upregulation at
90 min (Po0.05); however, no significant difference between
the groups was found at later time points. The expression of
HO-1 by immunohistochemistry paralleled the mRNA levels
(data not shown). Further, we measured the mRNA levels of
E-selectin, IL-8, macrophage inflammatory protein-2 (MIP-2),
TNF-a, and monocyte chemoattactant protein-1 (MCP-1)
(Figure 7b–f). E-selectin mRNA was significantly elevated at
90 min after I/R, reached a maximum at 6 h and returned to
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Figure 3 | Effects of IL-13 on morphological and functional changes at day 1 after renal I/R. Two days after treatment with saline,
RGD-AdTL (control groups) or RGD-AdTIL-13, rats were subjected to 45min unilateral renal ischemia, followed by 24 h of reperfusion. (a, b)
Semiquantitative analysis of renal morphology showed significant reduction in tissue damage under RGD-AdTIL-13 therapy compared to
control groups, both in the outer medulla and in the cortex. Boxes delineate 25th and 75th percentiles, lines within boxes represent medians,
and whiskers represent 10th and 90th percentiles, respectively. (c) The increment in plasma creatinine found after I/R was fully prevented by
RGD-AdTIL-13 therapy. (d) Creatinine plasma levels correlated positively with the histological damage in the rats subjected to I/R. *Po0.05
compared to both saline and RGD-AdTL-treated control groups (n¼ 6 per group, except for the RGD-AdTL treatment, where n¼ 5 per group).
Table 1 | Proliferation of renal tubular epithelial cells (Ki67
immunostaining) at day 1 after I/R injury
Sham I/R+saline
I/R+RGD-
AdTL
I/R+RGD-
AdTIL-13
Cortex 0.07±0.01 12.65±2.98 12.95±2.20 15.01±1.71
Outer medulla 0.08±0.01 16.79±4.81 15.87±2.81 19.15±0.66
I/R, ischemia–reperfusion; RGD-AdTIL-13, RGD-adenovirus-interleukin-13.
Data are given as mean±s.e.m. of Ki67-positive cells/ 400 field (n=6 per group,
except I/R+RGD-AdTL, where n=5).
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baseline by day 1. IL-8 mRNA was maximally upregulated at
90 min and 6 h, and returned to normal by day 14. Membrane
cofactor protein-1 mRNA was briefly upregulated at 90 min
and 6 h, returning to baseline by day 1. TNF-a mRNA
increased significantly at 90 min and remained elevated
throughout the follow-up period. MCP-1 mRNA rose
significantly at 6 h and returned to normal by day 4. RGD-
AdTIL-13 significantly reduced the levels of E-selectin, IL-8,
MIP-2, TNF-a, and MCP-1 mRNA compared to the control
groups (Po0.05).
IL-13 and IL-13 receptor expression in normal and I/R kidneys
The expression of IL-13 and the IL-13 receptor(R) chains
IL-13Ra1, IL-13Ra2, and IL-4Ra was investigated using real-
time PCR. Very low levels of IL-13 mRNA (approximately
1/1000 of those in thymus) were detected in normal and I/R
kidneys (data not shown), with no measurable difference
between the groups being found. The IL-13Ra2 mRNA levels
remained unchanged during I/R (data not shown), whereas
IL-13Ra1 mRNA was upregulated at 6 h, day 1, and day 4,
and IL-4Ra mRNA at 90 min and 6 h. RGD-AdTIL-13
therapy diminished IL-13Ra1 and IL-4Ra mRNA upregula-
tion compared with the saline treatment (Figure 7g and h,
respectively, Po0.05).
Localization of IL-13R was investigated using immuno-
histochemistry for IL-4Ra subunit. In normal kidneys,
staining was found at the apical side of tubular epithelial
cells in the cortex and the outer medulla (Figure 8a).
Glomeruli, the interstitium, and blood vessels were negative.
At 90 min after I/R, the tubular staining was virtually normal,
whereas some de novo staining was detected in a few
interstitial infiltrating cells (Figure 8c). From 6 h onward,
the amount of tubular staining decreased, being absent in
necrotic/apoptotic cells at 6 h and day 1, and diminished in
dilated tubules at day 4 and 14 (Figure 8d). This was
accompanied by an increase in the number of positive
interstitial cells, with a maximum being reached at day 4
(Figure 8d); however, being still present at day 14. IL-13-
treated animals maintained a rather normal pattern of
IL-4Ra staining, with a limited decrease in tubular staining
and reduced number of positive infiltrating cells in
comparison with control I/R kidneys (data not shown).
DISCUSSION
This study shows hIL-13 systemic gene therapy to protect
against warm I/R injury in rat kidneys. Intramuscular gene
delivery of hIL-13 before I/R protected the kidneys from
structural deterioration, diminished inflammatory cell infil-
tration, and reduced local expression of several proinflam-
matory cytokines and chemokines. To the best of our
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Figure 5 | Inhibitory effects of IL-13 on interstitial prefibrosis
(a-SMA) and fibrosis (collagen III) after I/R injury. (a) Morphometrical
analysis of a-SMA staining in the I/R kidneys showed significantly less
a-SMA expression in the rats treated with RGD-AdTIL-13 compared to
saline and RGD-AdTL. (b) Reduced collagen III deposition at day 14
after I/R was found in the rats treated with RGD-AdTIL-13, in
comparison with saline and RGD-AdTL groups, *Po0.05 (n¼ 6 per
group, except for the RGD-AdTL treatment, where n¼ 4–5 per group).
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knowledge, this study is the first to substantiate the ability of
IL-13 to curtail I/R-induced damage in the kidney.
The pathophysiology of renal I/R injury involves a complex
temporal interplay between tubular and endothelial cell
damage, inflammation, and microvascular blood flow. The
initial region affected by I/R injury is the outer medulla,
representing the area of the S3 segment of the nephron, which
is the most sensitive to ischemic damage.6 Simultaneously, I/R
injury will affect endothelial cells.34 Both initial events were
observed after I/R, as demonstrated by histological analysis and
a marked increase in KIM-1 expression, and an early up-
regulation of E-selectin mRNA, respectively. Further, I/R injury
triggers an inflammatory response,7 which we evidenced by the
upregulation of IL-8, MIP-2, TNF-a, and MCP-1 mRNA and
the influx of neutrophils and macrophages. Inflammation
crucially contributes to activation and proliferation of resident
fibroblasts,12 as documented by the expression of interstitial
a-SMA, followed by the deposition of collagen III. The
macrophage influx paralleled the changes in a-SMA, in
agreement with the prerequisite of macrophage presence for
the development of fibrosis after renal damage.35 In addition,
the morphological changes were accompanied by impairment
of renal function, as demonstrated by an increase in plasma
creatinine levels at day 1, despite one functional kidney still
being present.
Systemic gene therapy with IL-13 markedly reduced all
these changes. The beneficial effects of IL-13 in I/R injury
have been demonstrated previously in several models of liver
ischemia19,22,23 and ascribed to the cytoprotective and anti-
inflammatory actions of IL-13, through a HO-1-dependent
mechanism.33 In our study, IL-13 did not upregulate HO-1
expression, suggesting that other factors are here at play.
As neutrophils are central players in I/R injury, the
observed reduction of neutrophil influx may account for a
major part of the protective effect of IL-13, as documented
earlier in hepatic I/R injury.22,23 One mechanism involved
herein may be a diminished production of neutrophil
chemoattractant factors, such as IL-8 and MIP-2, by the
injured kidney, as found in our study. Expression of IL-836
and MIP-237 in I/R kidneys was demonstrated previously;
however, this is the first evidence for an inhibitory effect of
IL-13 on their renal expression. In addition, reduced
neutrophil adherence to the vascular endothelium may limit
their influx at the site of damage. In this respect, we found a
strong reduction of E-selectin upregulation under IL-13
treatment. E-selectin is crucial in the process of rolling and
the initial attachment of circulating leukocytes, and it has
been associated with I/R injury.10,23,38 Accordingly, IL-13
diminished rolling/adhesion of neutrophils in a neutrophil/
HUVEC (human umbilical vein endothelial cells) adherence
assay39 and in liver I/R.19
Moreover, IL-13 may also be protective through inhibition
of TNF-a expression. Local TNF-a is produced during I/R by
both resident and infiltrating cells,40 and early blockade of
TNF-a preserves renal structure and function after I/R.41 We
found reduced TNF-a mRNA levels already at 90 min after
I/R, which was apparently produced by local renal cells, as a
significant influx of leukocytes was not yet present.
Interleukin-13 also limited macrophage infiltration, an
effect due, at least partially, to reduced expression of MCP-1,
a chemokine that crucially promotes infiltration and
activation of macrophages in inflammatory processes,42
including renal I/R in the kidney.43 However, as one of the
roles of macrophages is to clear neutrophils from the tissue,
their reduced influx may be secondary to the decreased
infiltration of neutrophils early after I/R.
In addition to limiting their influx, IL-13 may also influence
directly the function of infiltrating or circulating inflammatory
cells. IL-13 reduces production of proinflammatory cytokines,
such as IL-1, TNF-a, IL-6, IL-8, and MIP-1a,14,15,44 and
induces expression of IL-1 decoy receptor16,45 by neutrophils
and macrophages. Furthermore, although no effect on
oxidative burst has been demonstrated for neutrophils,46,47
IL-13 decreases respiratory burst in macrophages.48
Are the effects of IL-13 seen in our study locally or
systemically mediated? The existing literature suggests that
IL-13 acts directly on renal cells, although the nature of the
IL-13 effect (protective or deleterious) varies with the
experimental model. In vitro, IL-13 stimulates production
of RANTES (regulated upon activation, normal t-cell
expressed and secreted) by human renal tubular epithelial
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Figure 6 | Inhibitory effect of IL-13 on inflammatory cell
infiltration after renal I/R. (a) Neutrophils (HIS-48-positive cells)
infiltrated the kidneys already at 6 h of reperfusion, reached a
maximum at day 1, and returned to normal by day 14. (b)
Macrophages (ED-1-positive cells) infiltrated the kidneys later
compared to the neutrophils, reaching a maximum at day 4 after I/R
and being still abundantly present at day 14. Treatment with RGD-
AdTIL-13 significantly diminished both neutrophil and macrophage
infiltration compared to saline and RGD-AdTL-treated animals,
*Po0.05 (n¼ 6 per group, except for the RGD-AdTL treatment, where
n¼ 4–5 per group).
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cells,49 whereas it induces secretion of proteinase cathepsin and
Hþ by mesangial cells.50 In vivo, in glomerulonephritis, IL-13
limits humorally mediated injury51 and reduces macrophage
influx,52 whereas its renal upregulation protects from renal
failure in sepsis.20 Here, we show that the IL-13R subunit
IL-4Ra is expressed in normal and I/R kidneys by tubular
epithelial cells. This is in agreement with the observed effect of
IL-13 on IL-8, MIP-2, and MCP-1, which are primarily
produced by tubular epithelial cells.36,37,43 Surprisingly, no
IL-4Ra expression was seen in endothelial cells. As we did
document decreased E-selectin under IL-13 treatment, it may
well be that the level of IL-4Ra expression in renal endothelial
cells is too low to be detected by immunohistochemistry or
that E-selectin decrement was secondary to the action of a
molecule induced systemically or locally by IL-13. Thus, given
the presence of IL-13 receptor on the primary target of I/R
(tubular epithelial cells) and the attenuation of the very early
response to I/R, that is, in advance of the influx of neutrophils
and macrophages, it seems conceivable that the IL-13 effects
are at least partly mediated by direct action on renal cells.
In conclusion, we showed that systemic gene therapy with
IL-13 substantially diminishes renal tubulointerstitial damage
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and inflammation induced by I/R. This finding may provide
novel pathways of therapeutical intervention in human renal
disease, especially in kidney transplantation, where IL-13
could be locally overexpressed by means of gene therapy.
MATERIALS AND METHODS
Animal model
Male Wistar rats (Harlan, Horst, The Netherlands) weighing
250–300 g were used. The animal experimental protocols
were approved by the Animal Research Ethics Committee of
the University Medical Center Groningen (Groningen, The
Netherlands). Two days before I/R (day 2), rats received intra-
muscular 4 1011 viral particles (VP) adenovirus-IL-13 (n¼ 6
per group), adenovirus control (n¼ 4–5 per group), or saline (n¼ 6
per group). The adenovirus was injected 2 days before I/R, as in a
pilot study conducted in normal (non-I/R) rats, we found maximal
IL-13 expression around day 2 after intramuscular administration of
adenovirus-IL-13. On day 0, rats underwent clamping of the left
renal pedicle for 45 min, followed by reperfusion for 90 min, 6 h, 1,
4, or 14 days. The sham-operated rats underwent dissection of the
left renal pedicle without clamping. Blood samples were collected
via the tail vein at day 2 and day 0, and at the time of killing from
aorta, followed by perfusion with saline. A midcoronal slice of the
kidneys as well as other organs and hind leg muscles were fixed in
4% paraformaldehyde and processed for paraffin embedding. From
the I/R kidneys, a second midcoronal slice was snap-frozen in liquid
nitrogen and stored at 80 1C for RNA isolation and cryostat
sections.
Adenoviral vectors
A first generation recombinant adenovirus type 5 harboring an RGD
sequence in the HI loop28 was kindly provided by Dr David T Curiel
(University of Alabama at Birmingham, Birmingham, Alabama,
USA). The adenovirus contains the genes for GFP (T) and firefly
luciferase (L) under the control of a CMV (cytomegalovirus)
promoter, in the E1 region (RGD-AdTL). To construct the IL-13
vector, the cDNA of hIL-13 gene was cloned into the shuttle plasmid
pAdTrack-CMV.53 Using homologous recombination in Escherichia
coli BJ5183, the shuttle was integrated into the RGD adenovirus
plasmid pVK503,54 resulting in a RGD-modified adenovirus genome
with GFP and hIL-13 under the control of a CMV promoter (RGD-
AdTIL-13). Adenoviruses were propagated on 293 cells, purified,
and tittered as described previously.55 The ratio VP/p.f.u. (plaque
forming units) was approximately 130/1. The expression of hIL-13
by RGD-AdTIL-13 was confirmed in supernatants of 293 cells
transduced in vitro, using ELISA (enzyme-linked immunosorbent
assay) (data not shown).
ELISA
The IL-13 plasma levels were measured using an ELISA kit for hIL-
13 (Diaclone, Cedex, France), according to the manufacturer’s
recommendations. To study the crossreactivity of the anti-hIL-13
antibody with rIL-13, known amounts of recombinant rIL-13 were
included in the assay. No crossreactivity was found. In addition, the
rIL-13 plasma levels were measured using a rIL-13 ELISA kit
(Biosource, Nevilles, Belgium).
Histopathology and plasma creatinine
Paraffin sections (3 mm) from kidneys reperfused for 1 day were
dewaxed and stained with periodic acid-Schiff (PAS). Histological
changes were evaluated by assessment of four markers of damage
associated with I/R injury: tubular necrosis, loss of brush border,
denudation of basement membrane, and intraluminal casts. The
morphological changes were evaluated in the outer medulla (15
fields at original magnification  400) and the cortex (25 fields at
original magnification  400) by an observer blinded for the
groups. Each parameter was graded on a scale from 0 to 3, according
to the extent of injury (0:o5%; 1: 5–25%; 2: 25–75%; 3: 475%). A
histological score was calculated as the mean of the four parameters,
separately for the outer medulla and the cortex. A total histological
score was calculated as the mean of the scores for the outer medulla
and the cortex, and used to study the correlation between renal
morphology and function.
Plasma creatinine levels at day 1 of reperfusion and in sham rats
were determined using a colorimetric test (Merck MEGA Analyzer;
Merck, Darmstadt, Germany).
Immunohistochemistry
To localize the infected cells after intramuscular injection of
adenoviruses, a GFP immunostaining55 was performed on sections
from various organs (kidneys, liver, spleen, heart, lung, gut, hind leg
muscles). To evaluate I/R damage, kidney sections were stained for
KIM-1 (tubular damage, rabbit polyclonal, generously provided by
Dr JV Bonventre, Brigham and Women’s Hospital, Boston, MA,
USA), ED-1 (macrophages),55 a-SMA (prefibrosis),55 collagen III
(fibrosis, rabbit polyclonal, Biogenesis Inc., Sandown, NH, USA),
HIS-48 (neutrophils),56 and Ki67 (proliferation, mouse monoclonal;
Immunotech, Marseille, France). IL-4Ra was localized using a
mouse monoclonal anti-IL-4Ra antibody (R&D Systems, Abingdon,
UK). Paraffin sections were dewaxed and subjected to antigen
retrieval in 0.1 M Tris/HCl buffer (pH 9.0) by overnight incubation
at 80 1C (KIM-1, ED-1, a-SMA, and collagen III), by microwave-
Normal kidney Control Ig
I/R (90 min) I/R (day 4)
a
c
b
d
Figure 8 | Immunohistochemical localization of IL4Ra in normal
and ischemic–reperfused (I/R) kidneys. In normal kidneys, IL4Ra
was localized at the apical side of the proximal tubular epithelial cells
(a, brown, arrows). No staining was found when the primary antibody
was replaced by the same isotype Ig (b). Representative pictures from
I/R kidneys showing predominant tubular epithelial staining (arrows,
brown) with some positive staining in interstitial infiltrating cells
(arrowheads, brown) at 90min (c) and decreased staining in dilated
tubules (arrow) with increased staining in interstitial cells
(arrowheads) at 4 days (d) after I/R injury (original magnification
 400 for all pictures).
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induced heat (0.1 M Tris/HCl buffer, pH 9.0 for GFP and 10 mM
citrate buffer, pH 6.0 for Ki67), or by protease 0.1% (IL-4R). For
HIS-48, frozen sections (5mm) were cold-dried and fixed in acetone.
A two-step immunoperoxidase technique was used, as described
previously.55
Morphometry
Neutrophils were counted in 25 fields of the outer medulla, and
Ki67-positive cells were counted in 30 fields of the cortex and 25
field of the outer medulla, using an ocular grid at original
magnification  400. KIM-1, a-SMA, collagen III, and ED-1
immunostainings were quantified using computer-assisted morpho-
metry. Thirty (cortex, a-SMA, and collagen III) or 40 (the cortex
and medulla, ED-1; 15 outer medulla and 25 cortex, KIM-1) fields
were measured at original magnification  200. For neutrophils,
macrophages, and Ki67, the number of positive cells was expressed
as mean per field. For KIM-1, a-SMA, and collagen III, the total
staining was divided by the area measured and expressed as a
percentage.
RNA isolation and real-time PCR
Frozen kidney samples containing both the cortex and the medulla
were homogenized, and RNA was isolated using a Qiagen kit
(Qiagen, Venlo, The Netherlands). Integrity of RNA was determined
using agarose gel electrophoresis, and the RNA concentration was
measured spectrophotometrically at 260 nm. RNA (1 mg) was
reverse-transcribed, and cDNA was further used to analyze rat
IL-13, IL-13Ra1, IL-13Ra2, IL-4Ra, HO-1, IL-8, MIP-2, E-selectin,
TNF-a, and MCP-1 gene expression using a real-time PCR protocol,
as described previously.57 The sequences of the primers used are
given in Table 2.
Statistical analyses
Results are expressed as mean±s.e.m., if not stated otherwise. The
values of plasma creatinine were compared using analysis of variance
and the Student–Newman–Keuls post hoc test. The difference
between the tubular damage scores was analyzed by the Kruskall–-
Wallis test, followed by Dunn’s post hoc test. The levels of all the
other parameters studied were compared with repeated measure-
ments analysis of variance. Differences were considered statistically
significant at a two-sided Po0.05.
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